FDA Grants Fast Track Status To Amgen Heart Failure Drug Forbes Amgen announced yesterday that its new chronic heart failure drug ivabradine had been granted fast track status by the FDA. The company said the fast track designation, which is for drugs that treat serious conditions and fill an umet medical need ... |
